In this article top new literature in the field of infectious diseases and antimicrobial stewardship is identified. This monthly rundown can help you keep up with the latest and greatest material!
Written By: Bassam Ghanem, Pharm.D., MS, BCPS
Edited By: Timothy P. Gauthier, Pharm.D., BCPS-AQ ID
Last updated: 1 September 2019
In this monthly column two infectious diseases pharmacists who utilize Twitter to stay current with antimicrobial stewardship literature (@ABsteward [B.G.] & @IDstewardship [T.G.]) identify some of the top new hot off the press articles recently published.
The following are some of the new publications we found most interesting or noteworthy that were released in August of 2019. We get to learn each month from all of these amazing publications and hope you enjoy this list as much as we enjoy putting it together!
1. RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections | CID
RESTORE-IMI 1 RCT concluded that IMI/REL had comparable efficacy but significantly less nephrotoxicity compared with colistin-based therapy for treatment of carbapenem-nonsusceptible gram-negative infections.
2. Daptomycin plus beta-lactam combination therapy for methicillin-resistant Staphylococcus aureus bloodstream infections: a retrospective, comparative cohort study | CID
This multicenter retrospective study found that the addition of a beta-lactam to daptomycin was associated with improved clinical outcomes in patients with MRSA BSI.
3. Oral Fluoroquinolone or Trimethoprim-sulfamethoxazole vs. Beta-lactams as Step-Down Therapy for Enterobacteriaceae Bacteremia: Systematic Review and Meta-analysis | OFID
This systematic review concluded that there is a superiority of fluoroquinolones over oral beta-lactams in the IV to oral step-down treatment of GNR bacteremias , however there was insufficient data regarding outcomes after oral TMP-SMX in this setting.
4. Risk Factors and Outcomes Associated With Treatment of Asymptomatic Bacteriuria in Hospitalized Patients | JAMA Internal Medicine
This large retrospective cohort study of hospitalized adults with ASB found that 82.7% received inappropriate antibiotic treatment. Antibiotic treatment was associated with a 37% longer duration of hospitalization without improved clinical outcomes.
5. Time-Series Analysis of Health Care Associated Infections in a New Hospital With All Private Rooms | JAMA Internal Medicine
This time-series analysis found that the move to a new hospital with exclusively single-patient rooms appeared to be associated with a sustained decrease in the rates of new MRSA and VRE colonization and VRE infection without a reduction in CDI or MRSA infection.
6. Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial | Lancet ID
The OASIS 2 RCT concluded that once-daily oral omadacycline was non-inferior to twice-daily oral linezolid in adults with ABSSSI, plus was safe and well tolerated.
Additional New & Notable Publications
Contact precautions in single-bed or multiple-bed rooms for patients with extended-spectrum beta-lactamase-producing Enterobacteriaceae in Dutch hospitals: a cluster-randomised, crossover, non-inferiority study| Lancet ID
Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial | Lancet ID
Cefazolin Versus Anti-Staphylococcal Penicillins for the Treatment of Patients with Methicillin-Susceptible Staphylococcus aureus Infection: A Meta-Analysis with Trial Sequential Analysis | Infectious Diseases and Therapy